# fs-bioenergia-valuation
Valuation report (DCF) of FS Bioenergia – Ethanol &amp; Bioenergy Sector Analysis
# FS Bioenergia – Valuation Report (DCF)

# FS Bioenergia – Investment Memorandum

## Overview
This project presents a full investment analysis of FS Bioenergia, one of Brazil’s leading corn ethanol producers, structured as an Investment Memorandum.

The analysis evaluates industry positioning, competitive dynamics, regulatory framework, and intrinsic valuation using a Discounted Cash Flow (DCF) model.

---

## Company Profile
FS Bioenergia operates an integrated biorefinery model focused exclusively on corn ethanol production. The company has over 2.1 billion liters of annual capacity and diversified revenue streams including:

- Ethanol (hydrated and anhydrous)
- DDG (animal feed)
- Corn oil
- Energy co-generation
- CBIO monetization (RenovaBio)

---

## Industry & Regulatory Context

- Growing participation of corn ethanol in Brazil’s energy matrix
- RenovaBio carbon credit mechanism (CBIOs)
- Law 14.993/2024 – “Fuel of the Future”
- Long-term upside through SAF (Alcohol-to-Jet pathway)

---

## Investment Highlights

1. Market Leadership in Corn Ethanol
2. Integrated and Diversified Revenue Model
3. Structural Exposure to Decarbonization Trends
4. Export Optionality via DDG (China market access)
5. Strong Operating Margins (~22% EBIT)

---

## Valuation Summary

- Methodology: Discounted Cash Flow (DCF)
- Projection Period: 2026–2030
- WACC: 15%
- Terminal Growth Rate: 3%
- Implied Equity Value: R$ 7.19 billion

Sensitivity analysis performed on WACC and terminal growth rate.

---

## Key Risks

- Commodity volatility (crush spread)
- Regulatory risks (RenovaBio mandates)
- Capital intensity
- Competitive pricing dynamics

---

## Investment Recommendation

Based on industry tailwinds, integrated business model, and valuation output, the company presents an attractive long-term investment case, subject to commodity cycle risks.

---
## Value Creation Levers

Potential upside drivers include:

- Capacity expansion
- Operational efficiency gains
- SAF premium pricing
- CBIO price recovery
- Strategic deleveraging

## Disclaimer

This material was prepared for academic and portfolio purposes and does not constitute investment advice.
